BAAM
HAE icon

Baker Avenue Asset Management’s Haemonetics HAE Stock Holding History

Baker Avenue Asset Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3
Closed -$269 – 832
2023
Q3 		$269 Hold
3
– – ﹤0.01% 1573
2023
Q2 		$255 Hold
3
– – ﹤0.01% 1539
2023
Q1 		$248 Hold
3
– – ﹤0.01% 1591
2022
Q4 		$236 Buy
+3
New +$241 ﹤0.01% 1529

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baker Avenue Asset Management's HAE Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 3 shares — an estimated $269 sold.

Baker Avenue Asset Management first reported a position in HAE in Q4 2022 and held it in 4 quarters. The position peaked at $269 in Q3 2023. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 3 Haemonetics shares in Q4 2023, an estimated $269.
  • Baker Avenue Asset Management first reported a position in Haemonetics in Q4 2022 and held it in 4 quarters.
  • Baker Avenue Asset Management's Haemonetics position peaked at $269 in Q3 2023.
  • 295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.